Pfizer wins bid to invalidate GSK’s patents over RSV vaccine
Published by Uma Rajagopal
Posted on October 8, 2024

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Uma Rajagopal
Posted on October 8, 2024

LONDON (Reuters) – Pfizer on Monday won a bid in a London court to invalidate two of GSK’s patents relating to a respiratory syncytial virus (RSV) vaccine.
The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV, which typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults.
GSK separately sued Pfizer in the United States last year, alleging Pfizer’s vaccine violates GSK’s patent rights in its RSV shot Arexvy.
A GSK spokesperson said the ruling “has no impact on our ability to launch and market Arexvy anywhere in the world, including in the UK.
We continue to believe our patents are valid and infringed by Pfizer and will seek to appeal this decision,” the spokesperson added.
Pfizer welcomed the court’s decision.
Pfizer is pleased with the decision of the UK High Court finding certain GSK patents concerning RSV-related technology both invalid and not infringed,” a spokesperson said.
(Reporting by Sam Tobin; additional reporting by Maggie Fick; editing by Sarah Young)